1,075,673 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,075,673 shares of the company’s stock, valued at approximately $20,266,000. Point72 Asset Management L.P. owned about 2.33% of Pacira BioSciences at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. ProShare Advisors LLC increased its stake in shares of Pacira BioSciences by 30.2% in the fourth quarter. ProShare Advisors LLC now owns 16,003 shares of the company’s stock valued at $301,000 after buying an additional 3,710 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Pacira BioSciences by 109.9% during the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company’s stock worth $11,792,000 after buying an additional 327,754 shares in the last quarter. Numerai GP LLC bought a new position in shares of Pacira BioSciences during the 4th quarter worth approximately $296,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Pacira BioSciences by 3.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock worth $491,000 after buying an additional 794 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in shares of Pacira BioSciences during the 4th quarter worth approximately $8,558,000. Institutional investors own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PCRX shares. Barclays increased their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC lowered their price target on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, HC Wainwright increased their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $26.44.

Pacira BioSciences Trading Up 1.0%

Shares of Pacira BioSciences stock opened at $25.86 on Friday. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $31.64. The firm has a market cap of $1.20 billion, a PE ratio of -12.74 and a beta of 0.56. The stock has a fifty day moving average price of $24.88 and a 200-day moving average price of $22.40. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.